Compare · QTRX vs WAT
QTRX vs WAT
Side-by-side comparison of Quanterix Corporation (QTRX) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QTRX and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $36.23B, about 199.0x QTRX ($182.1M).
- Over the past year, QTRX is down 25.3% and WAT is up 31.0% - WAT leads by 56.2 points.
- QTRX has been more active in the news (9 items in the past 4 weeks vs 4 for WAT).
- WAT has more recent analyst coverage (25 ratings vs 13 for QTRX).
- Company
- Quanterix Corporation
- Waters Corporation
- Price
- $3.87-2.40%
- $368.77-2.33%
- Market cap
- $182.1M
- $36.23B
- 1M return
- +26.06%
- +2.25%
- 1Y return
- -25.29%
- +30.96%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- 1995
- News (4w)
- 9
- 4
- Recent ratings
- 13
- 25
Quanterix Corporation
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest QTRX
- Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 36,068 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Faessler Jason F.
- Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
- Director Mendel Scott converted options into 8,073 shares, increasing direct ownership by 51% to 24,056 units (SEC Form 4)
- Director Lai Goldman Myla converted options into 8,073 shares, increasing direct ownership by 116% to 15,041 units (SEC Form 4)
- Director Mendel Scott was granted 3,456 shares, increasing direct ownership by 26% to 16,837 units (SEC Form 4)
- Director Donnelly William P was granted 5,472 shares, increasing direct ownership by 4% to 160,305 units (SEC Form 4)
- Chief Technology Officer Miller Michael Francis converted options into 130 shares and covered exercise/tax liability with 39 shares, increasing direct ownership by 0.26% to 34,977 units (SEC Form 4)
- Chief Financial Officer Sriram Vandana covered exercise/tax liability with 548 shares and converted options into 1,833 shares, increasing direct ownership by 4% to 31,283 units (SEC Form 4)
Latest WAT
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)
- Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
- Bernstein resumed coverage on Waters with a new price target
- SVP Waters Analytical Sciences Carpio Robert L Iii covered exercise/tax liability with 189 shares, decreasing direct ownership by 5% to 3,426 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Waters Corporation
- IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
- Piper Sandler initiated coverage on Waters with a new price target
- Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis